Analysts Set Expectations for MREO FY2025 Earnings

Mereo BioPharma Group plc (NASDAQ:MREO) – Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for Mereo BioPharma Group in a research note issued to investors on Thursday, March 27th. Cantor Fitzgerald analyst K. Kluska expects that the company will post earnings of ($0.08) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $7.00 target price on the stock. The consensus estimate for Mereo BioPharma Group’s current full-year earnings is ($0.03) per share.

Several other brokerages have also commented on MREO. Lifesci Capital started coverage on shares of Mereo BioPharma Group in a research report on Tuesday, December 24th. They set an “outperform” rating and a $10.00 target price on the stock. Needham & Company LLC restated a “buy” rating and set a $7.00 target price on shares of Mereo BioPharma Group in a research report on Wednesday, March 26th. Jefferies Financial Group initiated coverage on shares of Mereo BioPharma Group in a report on Friday, December 6th. They issued a “buy” rating and a $7.00 target price for the company. Finally, JPMorgan Chase & Co. started coverage on Mereo BioPharma Group in a research note on Thursday, March 27th. They set an “overweight” rating and a $7.00 price target on the stock. Six research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $7.71.

Mereo BioPharma Group Price Performance

Mereo BioPharma Group stock opened at $2.17 on Monday. The stock’s 50 day moving average price is $2.69 and its 200 day moving average price is $3.45. The company has a market cap of $336.67 million, a PE ratio of -36.17 and a beta of 1.03. Mereo BioPharma Group has a 1-year low of $2.11 and a 1-year high of $5.02.

Mereo BioPharma Group (NASDAQ:MREO) last released its earnings results on Wednesday, March 26th. The company reported ($0.01) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.03).

Institutional Trading of Mereo BioPharma Group

Institutional investors and hedge funds have recently modified their holdings of the business. Newbridge Financial Services Group Inc. acquired a new position in shares of Mereo BioPharma Group during the 4th quarter worth approximately $37,000. Jump Financial LLC purchased a new position in Mereo BioPharma Group during the fourth quarter worth $39,000. Sheets Smith Investment Management purchased a new position in Mereo BioPharma Group during the fourth quarter worth $59,000. Virtus ETF Advisers LLC acquired a new position in shares of Mereo BioPharma Group in the fourth quarter worth $67,000. Finally, Avanza Fonder AB purchased a new stake in shares of Mereo BioPharma Group in the fourth quarter valued at $69,000. Hedge funds and other institutional investors own 62.83% of the company’s stock.

Mereo BioPharma Group Company Profile

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors.